Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + epoetin alfa + vinorelbine
- Development stage
- Unknown
- Lead developer
- Michigan State University
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination involves **cisplatin**, a platinum-based chemotherapy drug used to treat various cancers by interfering with DNA replication; **epoetin alfa**, a recombinant human erythropoietin that stimulates red blood cell production, used to treat anemia; and **vinorelbine**, a microtubule inhibitor that prevents cancer cell division. The combination is used to manage cancer while mitigating anemia associated with chemotherapy.
02
Targets
Erythropoietin ReceptorDNAMicrotubule
Beyond the preview
Go deeper on cisplatin + epoetin alfa + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + epoetin alfa + vinorelbine.